Dissemin is shutting down on January 1st, 2025

Published in

Elsevier, Annals of Oncology, 3(28), p. 555-561, 2017

DOI: 10.1093/annonc/mdw627

Links

Tools

Export citation

Search in Google Scholar

Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram

Journal article published in 2017 by F. Pietrantonio, R. Miceli, L. Rimassa, S. Lonardi, G. Aprile, A. Mennitto, F. Marmorino, S. Bozzarelli ORCID, L. Antonuzzo ORCID, E. Tamburini ORCID, F. Morano, D. Rossini, F. Battaglin, M. Baretti, R. Berenato and other authors.
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Upload
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

Regorafenib and TAS-102 have recently demonstrated statistically significant survival gains in patients with refractory metastatic colorectal cancer (mCRC). Life expectancy ≥12 weeks was an inclusion criterion in registrative trials, and the identification of proper clinical selection tools for the daily use of these drugs in heavily pre-treated patients is needed to improve the cost-benefit ratio. We aimed at building a nomogram able to predict death probability within 12 weeks from the date of assessment of refractory mCRC.